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Abstract: Unsafe sex with HIV-infected individuals remains a major route for HIV transmission,
and protective strategies, such as the distribution of free condoms and pre-or post-prophylaxis
medication, have failed to control the spread of HIV, particularly in resource-limited settings and
high HIV prevalence areas. An additional key strategy for HIV prevention is voluntary male circumcision (MC). International health organizations (e.g., the World Health Organization, UNAIDS)
have recommended this strategy on a larger scale, however, there is a general lack of public understanding about how MC effectively protects against HIV infection. This review aims to discuss the
acquisition of HIV through the male genital tract and explain how and why circumcised men are
more protected from HIV infection during sexual activity than uncircumcised men who are at higher
risk of HIV acquisition.
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1. Introduction
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Over the past four decades, major global efforts have been initiated to address the
HIV/AIDS epidemic, and significant progress has been made in terms of controlling the
disease spread and in therapeutics. Current treatment regimens are highly effective at
reducing the amount of HIV in the body (viral load) to very low and undetectable levels [1].
However, while current treatment regimens are very effective and have improved the life
expectancy of HIV-infected individuals, they fail to eradicate the virus from the body [2–9].
If treatment is halted, the virus re-emerges, even if it has been suppressed for many
years. This is because the virus can continue replicating in immune-privileged sites, where
the drugs have limited access (for example, the brain), and also because the virus can
establish latent infection [10]. Therefore, the infected individuals need to rely on highly
active antiretroviral therapy (HAART) for the rest of their life to suppress the viral load in
the blood.
To deal with HIV under this current scenario, prevention is the best strategy. Whilst
most HIV new infections are due to sexual transmission, prevention strategies like abstinence, using condoms during sex, taking prevention medicines such as pre-exposure
prophylaxis and post-exposure prophylaxis are some of the effective options to prevent HIV
infection. Nevertheless, these strategies are not always used nor are they always available,
and clinicians and policymakers are in search of alternative strategies in resource-limiting
settings and high HIV prevalence areas.
Studies (including clinical trials) have been conducted to investigate the effect of male
circumcision (MC) on the acquisition of HIV, and findings suggested that circumcised men
are at lower risk of acquiring HIV infection during sexual intercourse [11–13]. Moreover,
MC is also reported to be effective for preventing the spread of sexually transmitted
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diseases such as gonorrhea and syphilis [14]. In one study, medical MC reduced the risk
of acquisition of HIV by heterosexual men by 38% to 66% over 24 months [15]. Another
systematic and meta-analysis study in low and middle-income countries showed that
circumcision is more likely to protect (23% reduced odds of HIV infection) men who have
sex with men from HIV [16]. However, to implement this strategy on a larger scale, a wider
understanding is needed regarding the exact mechanism for how MC protects against
HIV infection. Thus, based on the literature available to date, this review discusses the
acquisition of HIV in the male genital tract and explains how and why circumcised men
are well protected from HIV infection during heterosexual activity, unlike uncircumcised
men who are at higher risk of HIV acquisition.
2. Anatomy of Male Genital Tract and Risk of HIV Infection
Men become infected with HIV mostly when they are involved in sexual interaction
with infected individuals through vaginal sex (insertive vaginal sex; 0.04%) [17] and anal
sex (insertive anal sex; 0.06–0.62%) [18] via their penis. This indicates that the penis plays an
important role in HIV transmission. Therefore, understanding the changes in the anatomy
of the penis during and after sexual intercourse becomes important.
2.1. Anatomy of the Male Genital Tract
The penis consists of the penile shaft, glans, urethral meatus, the inner and outer
foreskin surfaces, the frenulum, and the thin band [19]. The foreskin (prepuce) is the
double-layered fold of smooth muscle tissue, neurons, blood vessels, skin, and mucous
membrane part of the penis. The prepuce protects the glans penis and the urinary meatus.
The outside of the foreskin has a continuation of the skin on the shaft of the penis while the
inner foreskin is a mucous membrane. The foreskin is attached to the glans by a frenulum
which is a highly vascularized tissue of the penis. The penile shaft and outer foreskin
surfaces are keratinized and contain stratified squamous epithelium. In contrast, the inner
foreskin is a wet mucosal surface that is rich in Langerhans Cells (LCs). Moreover, the inner
mucosal surface of the foreskin is not keratinized and susceptible to abrasions, facilitating
the entry of infectious agents.
2.2. Exposure of Inner Foreskin and Trapping Infectious Secretion under Foreskin Increase the Risk
of Infection
During sexual intercourse, the foreskin of the penis is pulled back down the penile
shaft thereby the entire inner foreskin surface becomes exposed to the biological fluids
including the infected virginal secretions [19,20]. The inner surface of the human foreskin
is highly susceptible to HIV-1 infection [21]. As the inner foreskin is known to be rich
in immune cells, the act of sexual intercourse by an uncircumcised man with an infected
partner increases the chances of HIV infection by exposing a large surface area where HIV
transmission can occur [20].
After sexual intercourse with an infected partner, the penis returns to a flaccid state, in
which there is a high chance of trapping the infectious materials (infected vagina secretion)
in a moist, warm and favorable environment [20,22]. The inner lining of the prepuce is not
keratinized, thin, and easily torn, and has an abundance in HIV target cells. Therefore, this
inner lining of the prepuce and prepuce sac provides an extra surface for HIV infection.
2.3. Abundance of Immune Cells in the Inner Foreskin Increase the Risk of HIV Infection
A primary target of HIV infection, antigen-presenting cells (APC), are present in the
mucosa of the inner foreskin and urethra [19,23]. The penile foreskin has high densities of
Langerhans cells (LCs), dendritic cells, and also CD4 + T-cells along, with the co-receptors
CCR5 and CXCR4. Macrophages, another type of possible HIV target cells, are also reported
to be present, residing below the epithelium. Overall in the adult foreskin, 22.4%, 11.5%,
and 2.4% of the total cell population consisting of CD4 + T-cells, Langerhans cells (LCs)
(tissue-resident macrophages of the skin), and macrophages, respectively [20]. A study
had also reported that the human penis is an efficient mucosal effector site, containing cell
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subsets that are required to induce and generate specific and effective immune responses
against mucosal pathogens [24]. These immune cells of the inner foreskin normally fight
against the invading bacteria and pathogen. However, when these cells are exposed to HIV,
they provide a gate for HIV entry. Therefore, the inner foreskin is rich with HIV target cells,
and it traps infectious materials in the inner lining of the prepuce, factors that increase the
risk of HIV acquisition.
3. Cell-Free Transmission and Cell-Associated HIV Transmission
HIV transmission is either by cell-free virus particles or cell-cell contacts [25–27].
3.1. Cell-Free Transmission of HIV-1
HIV-1 transmission through a cell-free method involves the release of the viral particle
from the HIV-1 infected cells, which then infects the uninfected cells at a distance by
diffusion through the extracellular space cells (Figure 1a). HIV-1 infects the main subset of
T lymphocytes via binding to CD4, the cell receptors expressed by mononuclear phagocytes
and dendritic cells. The trimeric HIV-1 envelope glycoprotein (Env) is responsible for the
recognition of the cell receptors and its entry into the cytoplasm. Env is expressed as gp160
but proteolytically cleaved into gp120 and gp41 heterodimers. Three heterodimers of gp120
and gp41 are assembled forming the final trimeric Env spike [28]. The Env trimer readily
dissociates into gp120 and gp41 subunits that can specifically infect CD4+ cells, which
include T helper cells, macrophages, microglial cells, and dendritic cells (DCs). For cellular
entry, HIV needs to make contact through its envelope glycoproteins (gp120) with both
the receptor CD4 [29] and co-receptor either CCR5 [30] or CXCR4 [31]. Interaction with
the appropriate chemokine receptor CCR5 or CXCR4 triggers the conformational changes
resulting in the fusion between the viral and cellular membrane. Besides, immune cells,
such as Langerhans cells (LCs), dendritic cells (DCs) [23,32–35] T-cells, and macrophages
expressed CD4/CCR5 as principal receptors for HIV-1 [23,33–35] and other alternative HIV1 attachment receptors, such as the Dendritic Cell-Specific Intercellular adhesion molecule3-Grabbing Non-integrin (DC-SIGN) on DCs and C-type lectins langerin on LCs [34,36,37].
Cell-free HIV transmission allows the spread of the virus over a long distance as they are
unrestricted cell-cell contacts and permits an easier spread to a new host [38]. To spread the
HIV-1 efficiently through cell-free virus particles: HIV-1 gene expression should be high to
assemble and release the virus; cellular factors must be sufficiently expressed to support
the assembly and release; HIV-1 should be able to efficiently release into extracellular space,
and the extracellular virus should be able to stabilize, bind, and efficiently enter the target
cell. Once these factors are fulfilled, the transmission of HIV-1 is mostly carried out by
cell-free virus particles. If these factors are not fulfilled, cell-to-cell contact transmission
(contact-dependent) is enforced.
3.2. Cell-to-Cell HIV Infection
The delivery of HIV-1 particles to adjacent cells for the establishment of infection
via cell contacts is defined as cell-to-cell transmission. Cell-cell transmission of the virus
promotes the direct transmission of viruses between adjacent cells. The ability of infected
donor cells to infect the non-infected cells through cell-cell contact is described by the
concept of the virological synapse (VS) while the ability of a non-infected donor cell to
capture the virus and transfer it to a permissive target cell is defined as trans-infection [39].
In both these methods of transfer, unlike cell-free HIV-1 transmission, cell-cell contact
viral transmission does not allow the virus to go through various virus-limiting steps,
such as neutralizing antibodies and complement. The cell-cell transmission does not
require any rate-limiting of the virus life cycle, such as virion attachment. Therefore,
the direct cell-cell transmission of the virus is more efficient and rapid when compared
to cell-free spread [25]. Cell-cell contact promotes or enhances HIV infection. Studies
have also shown that HIV spreads more efficiently by utilizing direct cell-cell contact
in vitro [27,40,41]. It leads to maybe 100–1000-fold more efficient infection than cell-free
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viral particles infection [40,42–44]. High-multiplicity of infection at the contact site, efficient
integration, and accelerated viral gene expression in the target cell are some of the factors
that enhance the efficiency of cell-to-cell HIV infection [38,45–47]. In addition, unlike
cell-free virion transmission, cell-cell transmission could also increase the likelihood of
Pathogens 2021, 10, x FOR PEER REVIEW
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Cell-cell contact among the HIV-infected and uninfected cells enhances infection
through specialized structures called virological synapses (VS) (Figure 1b). VS are molecularly organized cellular junctions that form between the infected (“donor”) and uninfected (“target”) cells to allow cell-to-cell viral transmission. VS provides a tight cleft be-
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T cells and target CD4 + T cells [41]. Interactions between infected and uninfected T
cells enhance HIV infection as the virus can escape neutralizing antibodies. It has been
studied in vitro that HIV is transferred between the infected and uninfected immortalized
CD4 + T cell lines; between infected CD4 + T cells and epithelial cells; between viruspulsed dendritic cells and CD4 + T cells, and between infected macrophages and epithelial
cells and CD4 + T cells.
3.2.2. Virus Transmission through Trans-Infection
The major pathogenic process of HIV-1 is the capture of HIV-1 by APCs such as
myeloid DCs, macrophages [49–52], and B lymphocytes [53,54] and then the transfer of
HIV-1 to CD4+ T cells, resulting in high levels of virus replication in the T cells [55].
In the case of trans-infection, viruses are captured by a cell without infecting itself and
then presented to a target cell through infectious synapse (Figure 1c). Soon after the
initiation of cell-cell contact, cellular receptor and cell adhesion molecules are accumulated
at the contact site to form a long-lasting contact for viral transfer. It was also reported
that monocyte-derived DCs (MDDCs) bind HIV particles in vitro and subsequently form
infectious synapses with virus receptor-expressing T cells. The outcome of the APC-to-T cell
trans infection process has been considered to be central to the sexual transmission of HIV-1
at mucosal (anal and vaginal) and epidermal (foreskin) sites. Studies have suggested that
this type of infection yields a high level of virus replication [56], and the viral production
in extracellular fluids from the target cells is much higher than that resulting from HIV-1
cis-infection [46].
4. Acquisition of HIV in the Male Genital Tract
The main problem in studying the acquisition of HIV in the male genital tract is the
lack of proper in-vitro viral transmission model systems that reflect the complex in-vivo
structure of such epithelia [34,57]. However, Dinh et al. explored possible sites of HIV-1
transmission in the penis by observing the interaction of HIV-1 particles with the adult
male foreskin and penile tissues from men and rhesus macaques [58]. To better understand
the kinetics and dynamics of HIV-1 transmission in men during heterosexual intercourse,
using epifluorescent microscopy, Dinh et al. visualized HIV-1 particles entering the penile
skin to depths where CD4 + T-cells are found. Moreover, a relatively large number of
HIV-1 particles were observed in and around the inner foreskin compared to the outer
foreskin. Furthermore, they visualized more HIV-1 particles entering the glans compared
to the foreskin tissues. These observations in foreskin tissue explants correlated with the
observations in the rhesus macaques. These observations suggest that the foreskin holds
the HIV-1 particles much longer, which accordingly, continues to infect the glans penis
over time. Although much attention has been focused on the foreskin as the main site
for HIV transmission, the penile shaft, glans, and urethra are all potential sites of HIV-1
entry and transmission to the penis during heterosexual intercourse. However, the exact
mechanisms for how viruses cross the primary barrier of genital epithelial cells (GECs)
remain unclear [59].
To describe the events of HIV-1 entry at the foreskin, Ganor et al. developed models
of the adult human foreskin epithelium [34,57]. Using the model, they explained the early
step involved in HIV entry in the male foreskin. The study has shown that the efficiency of
HIV-1 transmission is more in the inner foreskin than in the outer foreskin. The infectious
material is unable to penetrate the outer foreskin due to keratinization, which provides
a mechanical barrier against HIV [34]. Using confocal and fluorescence microscopy, they
showed that HIV particles remain trapped within the apical keratin layer of the outer
foreskin but able to penetrate the epidermal part of the inner foreskin [34].
The ability of HIV-infected cells to form VS with apical foreskin keratinocytes makes
the HIV-1 translocation more potent. In contrast, cell-free virion does not translocate
efficiently, and most of it becomes degraded when taken up by the cells (Figure 2a).
Therefore, the efficiency of HIV transmission in the male genital tract also depends on
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HIV induces chemokines CCL5/RANTES but decreases the secretion of CCL20/MIP-3alpha that facilitates the redistribution of LC [61]. The increased secretion of CCL5/RANTES
also enhances the recruitment of T cells from the dermis to the epidermis [61]. Studies
have shown that treatment with tumor necrosis factor-alpha in the inner foreskin of the
penis can also activate LC and stimulate cytokines that cause an influx of CD4 + T-cells
into the epithelial layer [62,63]. The newly recruited T cells form a conjugate with LC that
then transfers HIV-1 to other T-cells. Besides some external factors, the interaction of HIV
with the target cells causes the high permeability of HIV in the inner foreskin. Although
HIV can infect T cells without LC, the establishment of infection depends on its interaction
with LC. Therefore, when exposed to HIV, epidermal Langerhans cells migrate towards the
apical surface, internalize HIV, and then transfer it to T-cells (Figure 2c).
Studies have also shown that seminal plasma (SP) induces epithelial cells in the
female genitals to secrete chemokines that increase susceptibility to HIV-1 infection. SP
may modulate HIV transmission by either enhancing or inhibiting HIV infection and the
transfer of viruses [64,65]. Cervicovaginal secretion (CVS) contains a plethora of protective
innate factors against HIV-1 [57,66–68], indicating that genital fluids may directly modulate
HIV-1 transmission. Later on, either SP or CVS alone does not affect HIV-1 but the mixture
of SP and CVS does decrease HIV-1 entry in the foreskin, according to both in vitro and
in vivo studies [34]. Evidence has shown that STD in uninfected individuals have a
higher risk of getting HIV infection than individuals without any STDs [69,70]. It is worth
mentioning here that Chlamydia trachomatis and Neisseria gonorrhoeae are some common
STD human pathogens that infect the urethra in men and the cervix in women causing
mucosal inflammation [71–73]. These pathogens can invade their target epithelial cell that
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results in the production of proinflammatory cytokines by infected cells and then the influx
of various immune cells to the infection site. This process increases the amount of potential
HIV-1 target cells thereby enhancing the risk of HIV entry.
5. Male Circumcision (MC) and HIV Infection
Based on the biological explanation of HIV entry into the inner foreskin of the penis,
the surgical removal of the foreskin of the penis (MC) should reduce the risk of men
becoming infected with HIV. Therefore, various studies have been conducted relating to
the acquisition of HIV infection in circumcised males compared with uncircumcised males.
5.1. Randomized Clinical Trials (RCTs)
Randomized controlled trials (RCTs) have been carried out to determine the effect of
MC on HIV acquisition. One RCT recruited 3274 uncircumcised young (18–24 years old)
men in the semi-urban region of Johannesburg, South Africa., and then followed them for
up to 3, 12, and 21 months [11]. MC was offered to the intervention group immediately
after randomization and to the control group at the end of the follow-up [11]. The study
showed that MC protected against HIV acquisitions, equivalent to what a vaccine of high
efficacy would have achieved [11]. This trial concluded that MC may provide an important
way of limiting the spread of HIV infection in sub-Saharan Africa. This study also provides
the first experimental evidence of MC against HIV infection.
A study was then conducted at the Rakai district in Uganda to investigate the effect
of circumcision on the acquisition of HIV by 4996 uncircumcised HIV-negative men [74].
Almost half (2474 individuals) were randomly selected for MC and underwent immediate
circumcision while others were delayed circumcision for 24 months [74]. Follow-up information and HIV testing report were recorded for 6, 12, and 24 months. This study shows
MC reduced HIV incidence in men without behavioral disinhibition and concluded that
circumcision can be recommended for HIV prevention in men [74].
An RCT was also conducted to determine whether MC protects against HIV infection
and to assess the safety and changes in sexual behavior related to this intervention [12].
The 2784 young men in Kisumu, Kenya who participated were randomly classified into
two groups; the circumcision group (n = 1391) and the control group (delayed circumcision
groups, 1393) [12]. They were assessed by HIV testing, medical examinations, and behavioral interviews during follow-ups at 1, 3, 6, 12, 18, and 24 months [12]. The finding of this
study revealed that MC significantly reduces the risk of HIV acquisition in young men in
Africa (Table 1) [12].
Table 1. RCTs data showing the efficiency of MC.
Sl.no

RCT Study Site

Year

No. of Participants

Efficiency of MC

Ref

1.

Johannesburg, South Africa

2005

3274

60%

[11]

2.

Rakai district, Uganda

2007

4996

51–60%

[74]

3.

Kisumu, Kenya

2007

2784

53–60%

[12]

5.2. Safety, Complications, and Acceptability
One of the major concerns in expanding circumcision services is the safety of the procedure. If appropriate treatment is not provided or left unattended, then the complications
of MC can cause excessive pain, excessive bleeding, infection, too much skin removed,
anesthetic complications, cosmetic complications, erectile dysfunction, penile damage or
amputation, HIV infection, and even death [75]. The chances of complication are high if
MC is performed by an inexperienced person under aseptic conditions. Shortage of skilled
personnel, shortage of supplies, high cost in private sectors, shortage of dedicated space
for counseling, and surgery are some of the limitations for MC.
However, serious complications from MC are rare. The South African, Kenyan, and
Ugandan trials reported <4% MC complication rates among the participants. These clinical
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trials indicate that adult MC can also be safely undertaken even in limited-resource settings
if it is performed by well-trained providers [76]. To ensure safe MC, national clinical
protocols and quality assurance standards have been developed under the guidelines on
the provision of safe circumcision by WHO and UNAIDS [77,78]. As infant circumcision
is simpler and safer compared to adult circumcision, WHO and UNAIDS encourage
circumcision among infants.
Studies have also suggested that the acceptability rate of circumcision has increased up
to 80% in countries like Botswana, Kenya, Malawi, Tanzania, Zambia, South Africa, Uganda,
and Zimbabwe [79–81]. However, certain factors, like fear of infection and bleeding, pain,
and cost, remain barriers to MC. However, resistance to MC persists in some parts of the
world, particularly in Asian countries due to cultural practices [76].
5.3. Effect of MC on Sexual Function
Studies have been conducted to analyze the effect of MC on sexual functions. RCTs
in Kenya show that circumcision does not lead to sexual dysfunction among men while
RCTs conducted in Uganda show up to 2% of circumcised men had decreased in sexual
satisfaction or sexual dysfunction [82]. Nevertheless, men in the intervention group reported increased penile sensitivity and enhanced ease of reaching orgasm [83,84]. They
experienced improved sexual satisfaction and were very satisfied with the outcome of
circumcision. The study further suggested that, compared to uncircumcised men, MC has
no impact on the frequency of erectile dysfunction, ejaculation, pain during intercourse,
lack of pleasure with intercourse, or these dysfunctions combined. Studies from different
parts of the world have reported that MC causes no harm and increases sexual satisfaction
while a few studies have shown some degree of sexual dysfunction [85–88] Analysis from
systematic review relating to the pros and cons of MC revealed a high quality of evidence
that shows MC causes no harm in sexual functions [89].
Studies have also reported on findings from the sexual partner of circumcised males.
Studies from Uganda had indicated that women experienced either no change or an
increase in sexual satisfaction [90]. The vast majority of women (>95%) in Kenya reported
that they were very satisfied with the outcome of circumcision [84]. Studies from other
countries, like Malawi and Zambia, have also reported the increased female sexual pleasure
with a circumcised partner [91].
5.4. Evidence-Based Explanation of MC against the HIV Acquisition
Whether MC prevents men from acquiring HIV during heterosexual intercourse has
remained a subject of controversy. Claims have been made that circumcision is a wasteful
solution that distracts HIV-infected individuals from using other proven precautionary
measures. Thus, MC might result in higher HIV transmission if people start believing
it is an alternative precautionary method [50] and start engaging in unprotected sexual
activities [50–52]. A study was conducted to systematically evaluate the evidence against
MC. However, the finding of this study showed that circumcised men are less likely to
become infected with HIV [92].
Based on the evidence, various explanations have been made in support of circumcision. The first explanation is that the foreskin of the penis can retain the HIV-1 particles for
long periods, and accordingly, continue to infect the glans penis over time; therefore, the
removal of the skin covering the tip of the penis may decrease the man’s risk of acquiring
HIV infections [58]. Moreover, HIV susceptibility is reduced with the elimination of the
subpreputial space as it alters the local immune environment of the penile skin [93,94]. In
other words, circumcision reduces the surface area over which HIV-1 infection can take
place during heterosexual intercourse, and thus, removal of the foreskin by circumcision
reduces the risk for HIV infection.
Another explanation is that circumcision protects HIV-1 acquisition during heterosexual intercourse by reducing the HIV-1 target cells, especially in the inner foreskin
surface [21]. Since the inner foreskin mucosa contains a higher mean proportion of HIV-1
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target cells with HIV receptors, including CD4 + T-cells, macrophages, and LC [21,34,57,62],
it is considered as the point of HIV entry into the penis of an uncircumcised man; therefore,
removal of mucosal foreskin epithelium causes a dry keratinized epithelial surface which
is more resistant to HIV infection [95].
Furthermore, from an immunological perspective, uncircumcised men are more easily
infected by HIV and have higher levels of penile anaerobes compared to circumcised
men [96]. This finding further suggests that higher levels of penile anaerobes allow the
higher production of immune factors that recruit HIV target cells, such as CD4 + T-cells, to
the foreskin. This indicates that anaerobes may modify the risk of HIV infection by triggering inflammation [96]. Moreover, these anaerobes are shared by heterosexual partners and
thus associated with increased HIV risk [93,97,98]. For instance, Prodger and Kaul [93],
who recently described the immunological basis of how MC reduces HIV susceptibility,
observed that immune system activation in foreskin tissues next to subpreputial space
promotes HIV infection in uncircumcised men [93]. The role of the genital microbiome was
also determined to induce this immune activation [93], and indeed there was a correlation
between immune activation and the genital microbiome. These findings indicate that the
activation of LC to present HIV-1 to CD4 + T-cells was associated with anoxic surroundings of the subpreputial space. Therefore, in circumcised men, the reduction of anaerobic
bacteria protects against HIV infection.
Another study indicated that the uncircumcised penis is more susceptible to trauma,
with tearing of the frenulum and thin tissue of the prepuce that is not common in circumcised men [99]. Therefore, the removal of susceptible parts decreases the risk of HIV
infection. On an anatomical basis, the benefits of MC against HIV infection have been
proven by many investigators based on keratinization of the foreskin [20,21,33,58]. It is
now well documented that the keratinization of the inner foreskin is comparatively less
than the keratinization in the outer foreskin and because of this reason, uncircumcised men
more susceptible to HIV infection [20,33,58]. MC is also strongly supported by the data
from the three large RCTs conducted in Africa [11,12,74,100].
6. Conclusions
The HIV/AIDS epidemic remains a major disease challenge for the entire world.
Nevertheless, in the past four decades, continuous work has led to the development of
strategies for HIV/AIDS prevention and management. Despite progress in preventing
the spread of HIV in many parts of the world, there are still challenges since protective
strategies have failed to control the spread of HIV in many resource-limited settings and
high HIV prevalence areas. MC remains an important, evidence-based intervention for the
control of generalized HIV epidemics. There is overwhelming immunological evidence
in support of MC in preventing the heterosexual acquisition of HIV-1. Moreover, MC is
not a new, untested procedure but one of the oldest surgical procedures. It is also worth
mentioning that although MC is protective, this protection is indirect and it is not because
HIV-1 infection does not occur only over the foreskin, which is removed by circumcision,
but also through other tissues of the penis. Nevertheless, considering that there is currently
no cure for HIV, and neither is there a cheap, effective, and available preventive vaccine,
any level of protection against HIV infection is worthwhile.
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